Targeting Alpha‐Synuclein Aggregation With Chemical Chaperone IP‐045: An Approach to Parkinson's Disease Therapy
Drug Development Research · 2026-05 · 87 (3)
DOI: 10.1002/ddr.70288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 19.04.2026. Verfasst von Navpreet Kaur und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, Panjab University, Chandigarh, India. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Antiparkinson Agents, Indoles. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Indian Council of Medical Research (ICMR), Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Protein misfolding and aggregation of alpha‐synuclein (α‐syn) are central to Parkinson's disease (PD). Current therapies provide only symptomatic relief without addressing α‐syn aggregation. Chemical chaperones such as 4‐phenylbutyrate (4‐PBA) and tauroursodeoxycholic acid (TUDCA) show promise but are limited by toxicity and high dosage requirements. This study aimed to develop a safer, more effective multi‐target compound to counter α‐syn aggregation and related cellular stress. To design, synthesize, and evaluate a novel multi‐target chemical chaperone, IP‐045, for inhibiting α‐syn aggregation and ameliorating PD pathology. A structure‐based virtual screen of >11,000 compounds against the α‐syn fibril structure (PDB ID: 6UFR) identified four candidates with favorable pharmacokinetics. In vitro aggregation assays and SHSY5Y cell models assessed anti‐aggregation activity, cytotoxicity, and modulation of rotenone‐induced α‐syn expression, oxidative stress, and ER stress. The lead compound, IP‐045 (2‐Fluorophenyl 3‐(1H‐indol‐3‐yl)propanoate), was synthesized and tested in a rotenone‐induced PD rat model through behavioral, histological, and molecular analyses. IP‐045 strongly inhibited α‐syn aggregation in vitro with minimal cytotoxicity. In cell‐based assays, it reduced reactive oxygen species, ER stress markers, and α‐syn expression. In vivo, IP‐045 improved motor coordination, memory, and cognitive performance. Immunohistochemistry showed reduced Ser129‐phosphorylated α‐syn and restored tyrosine hydroxylase. IP‐045 also suppressed apoptotic and pro‐inflammatory markers in the substantia nigra, confirming multi‐target neuroprotective activity. IP‐045 demonstrated favorable anti‐aggregation and neuroprotective effects across in vitro and in vivo models, indicating its potential as a promising lead compound with chaperone‐like activity for targeting pathological processes associated with PD. Further pharmacokinetic, toxicity, and mechanistic studies are warranted to support its future therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics, Panjab University, Chandigarh, India.
- University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
ORCID-Profile: Tanzeer Kaur
Förderung
- Indian Council of Medical Research (ICMR)
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Kaur, N., Singh, R., Dhingra, N., & Kaur, T. (2026). Targeting Alpha‐Synuclein Aggregation With Chemical Chaperone IP‐045: An Approach to Parkinson's Disease Therapy. Drug Development Research, 87(3). https://doi.org/10.1002/ddr.70288
Vancouver
Kaur N, Singh R, Dhingra N, Kaur T. Targeting Alpha‐Synuclein Aggregation With Chemical Chaperone IP‐045: An Approach to Parkinson's Disease Therapy. Drug Development Research. 2026;87(3). doi:10.1002/ddr.70288
BibTeX
@article{Kaur2026,
author = {Kaur, Navpreet and Singh, Rimaljot and Dhingra, Neelima and Kaur, Tanzeer},
title = {Targeting Alpha‐Synuclein Aggregation With Chemical Chaperone IP‐045: An Approach to Parkinson's Disease Therapy},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {3},
doi = {10.1002/ddr.70288}
}
EUVIMED